|
|
Primary Care Posts by Charity Evans, 2004 - 2005
Wednesday, April 06, 2005
Insulin lispro is rapidly becoming considered a first-line choice for those patients with diabetes who require insulin therapy -- especially in children with Type I diabetes. However, in Saskatchewan, lispro does not currently have formulary status, and as such requires Exceptional Drug Status (EDS) in order to be covered by the provincial drug plan. Coverage is available for those patients who have an insulin pump, or those patients with difficult to control diabetes. In most cases a patient must be tried on regular insulin before they can be granted EDS for lispro.
With the 2003 Canadian Diabetes Association's Clinical Practice Guidelines emphasizing the relationship between post-prandial glucose levels and macrovascular complications, the focus has shifted somewhat to ensuring that patients' glucose levels are optimized post-prandially --often through the use of lispro insulin.
Because of this, we believe that lispro insulin has now become a candidate for formulary status, and have drafted a paper on this issue, which we recently submitted to the Saskatchewan Prescription Drug Plan for their review and consideration.
[Link]
Monthly Archives
01/01/2004 - 02/01/2004
02/01/2004 - 03/01/2004
03/01/2004 - 04/01/2004
04/01/2004 - 05/01/2004
05/01/2004 - 06/01/2004
06/01/2004 - 07/01/2004
07/01/2004 - 08/01/2004
08/01/2004 - 09/01/2004
09/01/2004 - 10/01/2004
10/01/2004 - 11/01/2004
11/01/2004 - 12/01/2004
12/01/2004 - 01/01/2005
01/01/2005 - 02/01/2005
02/01/2005 - 03/01/2005
03/01/2005 - 04/01/2005
04/01/2005 - 05/01/2005
05/01/2005 - 06/01/2005
06/01/2005 - 07/01/2005
07/01/2005 - 08/01/2005
|
|
|
Pharmacist Links
Saskatchewan
Health
Department of Health for Government of Saskatchewan
Canada
Pharmaceutical
National Association for Canada’s
Research-Based Pharmaceutical Companies
NAPRA
National
Association of Pharmacy Regulatory Authorities |
|
